ABCB1 and non-small cell lung carcinoma: A recent study suggested that direct inhibition of PI3K using the specific inhibitor BAY-1082439 or knockout of PI3K 110α or 110β downregulates MDR1 expression independently of the AKT pathway in non-small cell lung cancer (NSCLC) [35].